SCHEDULE: Affinity Funds Report 5.47% Stake in Verrica Pharmaceuticals
Beneficial Ownership Report (Schedule 13G)
Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP have disclosed a combined beneficial ownership of 5.47% in Verrica Pharmaceuticals Inc.
Summary
- Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP collectively beneficially own 884,172 shares of Verrica Pharmaceuticals Inc. common stock.
- This ownership represents 5.47% of Verrica Pharmaceuticals Inc.'s outstanding common stock.
- The total beneficial ownership comprises 707,338 shares of common stock and exercisable warrants to purchase an additional 176,834 shares of common stock.
- The percentage of class is calculated based on 16,166,695 shares of common stock outstanding as of November 25, 2025.
- The outstanding share count includes 9,490,035 shares as of November 7, 2025, and 6,499,826 shares issued in a private placement as of November 24, 2025, plus the 176,834 shares from warrants held by the Fund.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant institutional ownership stake, which is generally viewed as a positive signal of confidence in the company, though it contains no operational or financial updates from the issuer.
Positives
- Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP have taken a significant 5.47% stake in Verrica Pharmaceuticals Inc., indicating institutional confidence in the company.
- The investment includes both common stock and exercisable warrants, suggesting a long-term interest and potential for increased ownership.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Verrica Pharmaceuticals Inc. or the reporting persons regarding the issuer's future performance.
Management Comments
- Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer of Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP, certified that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Industry Context
This filing reflects an institutional investment in a pharmaceutical company, a common occurrence in the sector as funds seek opportunities in healthcare innovation and growth. It does not provide broader industry trend analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Affinity Asset Advisors and Affinity Healthcare Fund may be viewed positively, potentially increasing investor confidence and liquidity.
- Company Management: Increased institutional ownership can lead to greater scrutiny and engagement from large investors regarding corporate strategy and performance.
Key Dates
| Date | Description |
|---|---|
| 2025-11-07 | Date of outstanding shares reported in Issuer's Form 10-Q (9,490,035 shares). |
| 2025-11-14 | Date Issuer's Form 10-Q was filed with the SEC. |
| 2025-11-24 | Date Issuer's Form 8-K was filed with the SEC, detailing a private placement. |
| 2025-11-25 | Date of event requiring the filing of this statement and the basis for the outstanding share calculation (16,166,695 shares). |
| 2025-12-03 | Date of signing for Affinity Asset Advisors, LLC and Affinity Healthcare Fund, LP. |
Keywords
Verrica Pharmaceuticals, Affinity Asset Advisors, Affinity Healthcare Fund, Institutional Ownership, Common Stock, Warrants, Beneficial Ownership, SEC Filing, Schedule 13G, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.